Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase

There is currently no effective pharmacological treatment for amyotrophic lateral sclerosis (ALS). Because evidence suggests that multiple pathways may contribute to ALS pathogenesis, we tested in a mouse model of ALS (SOD1G37R mice) a combination approach consisting of three drugs for distinct targets in the complex pathway to neuronal death: minocycline, an antimicrobial agent that inhibits microglial activation, riluzole, a glutamate antagonist, and nimodipine, a voltage‐gated calcium channel blocker. The efficacy of this three‐drug cocktail was remarkable when administered in the diet from late presymptomatic stage (8–9 months). It delayed the onset of disease, slowed the loss of muscle strength, and increased the average longevity of SOD1G37R mice by 6 weeks. The protective effect of the treatment was corroborated by the reduced immunodetection signals for markers of gliosis and neurodegeneration in the spinal cord of SOD1G37R mice. These results indicate that such three‐drug combination may represent an effective strategy for ALS treatment. Ann Neurol 2003

[1]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[3]  P. Mattsson,et al.  Nimodipine promotes regeneration and functional recovery after intracranial facial nerve crush , 2001, The Journal of comparative neurology.

[4]  H. Schroeder,et al.  Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia , 2000, Neurosurgical Review.

[5]  S. Abramson,et al.  A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[7]  J. Nadler,et al.  The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. , 1993, European journal of pharmacology.

[8]  F. Joó,et al.  Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophc lateral sclerosis , 1996, Annals of neurology.

[9]  V. Ona,et al.  Minocycline Reduces Traumatic Brain Injury-mediated Caspase-1 Activation, Tissue Damage, and Neurological Dysfunction , 2001, Neurosurgery.

[10]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[11]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[12]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[13]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[14]  P. Mcgeer,et al.  Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. , 1992, The American journal of pathology.

[15]  W. Robberecht,et al.  Minocycline delays disease onset and mortality in a transgenic model of ALS , 2002, Neuroreport.

[16]  L. Komuves,et al.  Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons , 1995, Synapse.

[17]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[18]  M. Gurney,et al.  Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.

[19]  D. Cleveland,et al.  Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Olivier Curet,et al.  Beneficial Effects of Lysine Acetylsalicylate, a Soluble Salt of Aspirin, on Motor Performance in a Transgenic Model of Amyotrophic Lateral Sclerosis , 1999, Experimental Neurology.

[22]  J. Julien,et al.  Cell Cycle Regulators in the Neuronal Death Pathway of Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase 1 , 2003, The Journal of Neuroscience.

[23]  J. Julien,et al.  Deregulation of Cdk5 in a Mouse Model of ALS Toxicity Alleviated by Perikaryal Neurofilament Inclusions , 2001, Neuron.

[24]  Jeffrey D. Rothstein,et al.  From charcot to lou gehrig: deciphering selective motor neuron death in als , 2001, Nature Reviews Neuroscience.

[25]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[26]  Robert G. Miller,et al.  Controlled trial of nimodipine in amyotrophic lateral sclerosis , 1996, Neuromuscular Disorders.

[27]  Manuela G. López,et al.  Calcium Entry through L-type Calcium Channels Causes Mitochondrial Disruption and Chromaffin Cell Death* , 2001, The Journal of Biological Chemistry.

[28]  H. Horvitz,et al.  Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis , 1997, Annals of neurology.

[29]  X. P. Liu,et al.  A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. , 2000, Biochemical and biophysical research communications.

[30]  D. Schiffer,et al.  Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.

[31]  E. Stefani,et al.  Amyotrophic lateral sclerosis immunoglobulins increase Ca2+ currents in a motoneuron cell line , 1995, Annals of neurology.

[32]  J. Julien,et al.  Amyotrophic Lateral Sclerosis Unfolding the Toxicity of the Misfolded , 2001, Cell.

[33]  J. Julien,et al.  Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis , 2002, Neurobiology of Disease.

[34]  Reto Huber,et al.  Sleep deprivation in prion protein deficient mice and control mice: genotype dependent regional rebound , 2002, Neuroreport.

[35]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[36]  P. Stieg,et al.  Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.

[37]  B N Singh,et al.  The mechanism of action of calcium antagonists relative to their clinical applications. , 1986, British journal of clinical pharmacology.

[38]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[39]  S. Mignani,et al.  RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  A. Levey,et al.  Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.

[41]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[42]  W. Cunliffe,et al.  Safety of long‐term high‐dose minocycline in the treatment of acne , 1996, The British journal of dermatology.

[43]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.